Compare LUCY & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUCY | GNPX |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.5M |
| IPO Year | 2022 | 2018 |
| Metric | LUCY | GNPX |
|---|---|---|
| Price | $1.35 | $1.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 251.5K | ★ 277.6K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,392,547.00 | N/A |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.22 | N/A |
| 52 Week Low | $1.29 | $1.81 |
| 52 Week High | $7.08 | $55.00 |
| Indicator | LUCY | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 32.08 |
| Support Level | $1.36 | $2.51 |
| Resistance Level | $1.43 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 8.57 | 2.89 |
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.